CD3 Aptamer Targeting for T Cell Labeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and specific targeting of T cells for therapeutic and diagnostic applications, as existing technologies do not provide efficient means to selectively bind and modulate CD3 proteins on T cells.
Innovation Solution
Development of DNA and RNA aptamers that specifically bind to CD3 ε/γ or CD3 ε/δ protein complexes, allowing for targeted labeling, purification, or modulation of T cells, and their use in delivery vehicles for therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing targeting technologies are used for T cell targeting, then general cell targeting can be achieved, but specific and efficient binding to CD3 proteins is insufficient
Solution Approach 1:
The patent employs SELEX (Systematic Evolution of Ligands by EXponential enrichment) to iteratively optimize aptamer sequences, changing nucleic acid parameters through multiple selection rounds. This process transforms random nucleic acid sequences into high-affinity binders with specific CD3 targeting capability, resolving the contradiction between binding specificity and targeting efficiency
Solution Approach 2:
The patent creates synthetic nucleic acid copies (aptamers) that replicate the binding function of natural ligands but with enhanced properties. These aptamer copies can be chemically synthesized with controlled sequences that specifically recognize CD3 proteins, achieving both high specificity and efficiency that natural systems alone cannot provide
2Measurement precision
If aptamers are used for T cell targeting, then high specificity and affinity to CD3 proteins is achieved, but complexity in aptamer design and selection increases
Solution Approach 1:
The patent develops a universal SELEX platform that can select aptamers against multiple different targets using the same basic methodology. The process universally applies to various proteins and cell surfaces, reducing the perceived complexity by showing that the same systematic approach works across different applications
Solution Approach 2:
The patent divides the complex aptamer selection process into discrete, manageable segments: library preparation, selection rounds, amplification, and characterization. Each segment can be independently optimized and controlled, making the overall complex process more tractable and reproducible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers enable precise targeting and modulation of T cells, enhancing therapeutic delivery and diagnostic capabilities by providing high specificity and affinity to CD3 proteins, thereby overcoming the limitations of existing technologies.
Implementation Method 1
aptamers that bind to CD3 and can be used to target, label or sort T cells
Data Source
AI summary
High affinity aptamer sequences recognizing CD3 protein complex on cell surfaces are provided. The aptamers can be used as targeting moieties for delivery vehicles or as molecular components for immunotherapy, immunodiagnostics, or for isolating, purifying, or characterizing CD3+ T cells in a subject.